Repligen (RGEN) Total Non-Current Liabilities (2011 - 2026)
Repligen (RGEN) reported Total Non-Current Liabilities of $824.5 million for Q1 2026, up 15.37% year-over-year from $714.7 million in Q1 2025, and up 16.5% quarter-over-quarter from $707.7 million in Q4 2025.
Repligen (RGEN) Total Non-Current Liabilities (2011 - 2026) Analysis & Trends
Repligen (RGEN) has 16 years of Total Non-Current Liabilities data on file, last reported at $824.5 million in Q1 2026.
- Total Non-Current Liabilities for Q1 2026 came in at $824.5 million, up 15.37% year-over-year; the trailing twelve-month figure through Mar 2026 was $824.5 million (up 15.37% YoY), and the FY2025 annual result was $707.7 million, down 3.07% from the prior year.
- Total Non-Current Liabilities rose to $824.5 million in Q1 2026 per RGEN's latest filing, from $707.7 million in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $824.5 million in Q1 2026 and troughed at $170.1 million in Q3 2023.
- A 5-year average of $509.0 million and a median of $705.6 million in 2024 frame the typical range for Total Non-Current Liabilities.
- The sharpest annual moves came in 2023 and 2024: Total Non-Current Liabilities slipped 21.54% in 2023, then jumped 314.93% in 2024.
- A 5-year view of Total Non-Current Liabilities shows it stood at $216.7 million in 2022, then soared by 223.67% to $701.4 million in 2023, then increased by 4.1% to $730.2 million in 2024, then retreated by 3.07% to $707.7 million in 2025, then gained by 16.5% to $824.5 million in 2026.
- Business Quant data shows RGEN's Total Non-Current Liabilities at $824.5 million in Q1 2026, $707.7 million in Q4 2025, and $709.5 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Intuitive Surgical | 148.09 Bn | 143.69 Bn | 1.83 Bn | 1.91 Bn |
| 2 | Becton Dickinson | 41.00 Bn | 39.99 Bn | 2.15 Bn | 24.24 Bn |
| 3 | Medline | 30.38 Bn | 36.22 Bn | 1.84 Bn | 17.13 Bn |
| 4 | Resmed | 28.22 Bn | 26.56 Bn | 890.98 Mn | 941.16 Mn |
| 5 | West Pharmaceutical Services | 23.72 Bn | 23.19 Bn | 296.40 Mn | 1.03 Bn |
| 6 | Solventum | 13.33 Bn | 13.33 Bn | 1.10 Bn | 8.65 Bn |
| 7 | Cooper Companies | 13.12 Bn | 12.99 Bn | 735.40 Mn | 3.98 Bn |
| 8 | Align Technology | 12.86 Bn | 11.80 Bn | 736.59 Mn | 2.10 Bn |
| 9 | Baxter International | 10.51 Bn | 8.47 Bn | 891.00 Mn | 12.54 Bn |
| 10 | Repligen | 7.41 Bn | 6.42 Bn | 108.28 Mn | 824.53 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 824.53 Mn |
| Dec 31, 2025 | 707.74 Mn |
| Sep 30, 2025 | 709.49 Mn |
| Jun 30, 2025 | 716.87 Mn |
| Mar 31, 2025 | 714.66 Mn |
| Dec 31, 2024 | 730.16 Mn |
| Sep 30, 2024 | 705.59 Mn |
| Jun 30, 2024 | 706.76 Mn |
| Mar 31, 2024 | 706.55 Mn |
| Dec 31, 2023 | 701.40 Mn |
| Sep 30, 2023 | 170.05 Mn |
| Jun 30, 2023 | 211.85 Mn |
| Mar 31, 2023 | 204.67 Mn |
| Dec 31, 2022 | 216.70 Mn |
| Sep 30, 2022 | 216.73 Mn |
| Jun 30, 2022 | 216.03 Mn |
| Mar 31, 2022 | 193.09 Mn |
| Dec 31, 2021 | 233.03 Mn |
| Sep 30, 2021 | 176.69 Mn |
| Jun 30, 2021 | 80.55 Mn |